Ramatroban

Ramatroban

Systematic (IUPAC) name
3-((3R)-3-{[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9H-carbazol-9-yl)propanoic acid
Clinical data
Pregnancy cat.	?
Legal status	℞ Prescription only
Routes	Oral
Identifiers
CAS number	116649-85-5
ATC code	None
PubChem	CID 123879
IUPHAR ligand	1910
UNII	P1ALI72U6C^Y
ChEMBL	CHEMBL361812
Chemical data
Formula	C₂₁H₂₁F N₂O₄S
Mol. mass	416.46 g/mol
SMILES	eMolecules & PubChem

Ramatroban (INN) is a thromboxane receptor antagonist.^[1]

It is also a CRTH2 antagonist.^[2]

It is indicated for the treatment of coronary artery disease.^[3] It has also been used for the treatment of asthma.^[4]

It was developed by the German pharmaceutical company Bayer AG and is co-marketed in Japan by Bayer and Nippon Shinyaku Co. Ltd. under the tradename Baynas.

References

^ Sugimoto H, Shichijo M, Iino T et al. (April 2003). "An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro". J. Pharmacol. Exp. Ther. 305 (1): 347–52. doi:10.1124/jpet.102.046748. PMID 12649388. http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=12649388.
^ Royer JF, Schratl P, Carrillo JJ et al. (September 2008). "A novel antagonist of prostaglandin D2 blocks the locomotion of eosinophils and basophils". Eur. J. Clin. Invest. 38 (9): 663–71. doi:10.1111/j.1365-2362.2008.01989.x. PMID 18837743. http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0014-2972&date=2008&volume=38&issue=9&spage=663.
^ Fiedler VB, Seuter F, Perzborn E (December 1990). "Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease". Stroke 21 (12 Suppl): IV149–51. PMID 2260140.
^ Endo S, Akiyama K (November 1996). "[Thromboxane A2 receptor antagonist in asthma therapy]" (in Japanese). Nippon Rinsho 54 (11): 3045–8. PMID 8950952.

External links

(Japanese) Baynas

Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)

Antiplatelet drugs

Glycoprotein IIb/IIIa inhibitors	Abciximab • Eptifibatide • Tirofiban

ADP receptor/P2Y₁₂ inhibitors	thienopyridines (Clopidogrel, Prasugrel, Ticlopidine) • nucleotide/nucleoside analogs (Cangrelor, Elinogrel, Ticagrelor)

Prostaglandin analogue (PGI2)	Beraprost • Prostacyclin • Iloprost • Treprostinil

COX inhibitors	Acetylsalicylic acid/Aspirin^# • Aloxiprin • Carbasalate calcium • Indobufen • Triflusal

Thromboxane inhibitors	thromboxane synthase inhibitors (Dipyridamole, Picotamide) • receptor antagonist (Terutroban^†)

Phosphodiesterase inhibitors	Cilostazol • Dipyridamole • Triflusal

Other	Cloricromen • Ditazole

Anticoagulants

Vitamin K antagonists
(inhibit II, VII, IX, X)

coumarins: Acenocoumarol • Coumatetralyl • Dicoumarol • Ethyl biscoumacetate • Phenprocoumon • Warfarin^#

1,3-Indandiones: Clorindione • Diphenadione • Phenindione

other: Tioclomarol

Factor Xa inhibitors
(with some II inhibition)

Heparin group/ glycosaminoglycans/ (bind antithrombin)	low-molecular-weight heparin (Bemiparin, Certoparin, Dalteparin, Enoxaparin, Nadroparin, Parnaparin, Reviparin, Tinzaparin) oligosaccharides (Fondaparinux, Idraparinux) heparinoid (Danaparoid, Sulodexide, Dermatan sulfate)

Direct Xa inhibitors	xabans (Apixaban, Betrixaban, Edoxaban, Otamixaban, Rivaroxaban)

Direct thrombin (II) inhibitors

bivalent: Hirudin (Bivalirudin, Lepirudin, Desirudin)

univalent: Argatroban • Dabigatran • Melagatran^‡ • Ximelagatran^‡

Other

REG1 • Defibrotide • Ramatroban • Antithrombin III • Protein C (Drotrecogin alfa)

Thrombolytic drugs/
fibrinolytics

plasminogen activators: r-tPA (Alteplase, Reteplase, Tenecteplase) • UPA (Urokinase, Saruplase) • Streptokinase^# • Anistreplase • Monteplase

other serine endopeptidases: Ancrod • Fibrinolysin

Brinase

Non-medicinal

Citrate • EDTA • Oxalate

^#WHO-EM. ^‡Withdrawn from market. Clinical trials: ^†Phase III. ^§Never to phase III

M: MYL

cell/phys (coag, heme, immu, gran), csfs

rbmg/mogr/tumr/hist, sysi/epon, btst

drug (B1/2/3+5+6), btst, trns

Drugs for obstructive airway diseases: asthma/COPD (R03)

Adrenergics, inhalants

Short acting β₂-agonists	Salbutamol^#/Levosalbutamol • Fenoterol • Terbutaline • Pirbuterol • Procaterol • Bitolterol • Rimiterol • Carbuterol • Tulobuterol • Reproterol

Long acting β₂-agonists (LABA)	Arformoterol • Bambuterol • Clenbuterol • Formoterol • Salmeterol Ultra LABA: Indacaterol

other	Epinephrine^# • Hexoprenaline • Isoprenaline (Isoproterenol) • Orciprenaline (Metaproterenol)

Glucocorticoids

Beclometasone^# • Budesonide • Ciclesonide • Fluticasone • Mometasone • Flunisolide • Betamethasone • Triamcinolone

Anticholinergics/
muscarinic antagonist

Ipratropium bromide^# • Oxitropium bromide • Tiotropium bromide

Mast cell stabilizers

Cromoglicate • Nedocromil

Xanthines

Doxofylline • Enprofylline • Theobromine • Theophylline/Aminophylline/Choline theophyllinate

Eicosanoid inhibition

Leukotriene antagonists	Montelukast • Pranlukast • Zafirlukast

Lipoxygenase inhibitor	Zileuton

Thromboxane receptor antagonists	Ramatroban • Seratrodast

Combination products

Budesonide/formoterol • Fluticasone/salmeterol • Ipratropium bromide/salbutamol • Mometasone/formoterol

^#WHO-EM. ^‡Withdrawn from market. Clinical trials: ^†Phase III. ^§Never to phase III

M: RES

anat(n, x, l, c)/phys/devp

noco(c, p)/cong/tumr, sysi/epon, injr

proc, drug(R1/2/3/5/6/7)